OBJECTIVE： To investigate the situation and characteristics of drug use in patients with traumatic intracranial injury， and to provide reference for rational use of drugs in patients with traumatic intracranial injury. METHODS： By amount sorting analysis and DDDs analysis， electronic medical records of inpatients with traumatic intracranial injury in 192 hospitals during Jun. 1st 2016-May 31st 2017 were summarized and analyzed statistically in respects of demographics， diagnosis， drug information， etc. RESULTS： Among 26 011 patients with traumatic intracranial trauma， the male accounted for 72.4％ and the female accounted for 27.5％. The patients aged 31-50 years accounted for 57.0％. The traffic injury was the main injury factor （33.8％）， and high falling injury caused longest hospitalization day and highest cost. Top 3 types of traumatic intracranial injury in the list of diagnosed diseases ratio were unspecified intracranial injury （55.3％）， concussion （19.6％）， diffuse brain injury （13.0％）， among which average hospitalization day， average hospitalization cost and drug cost of patients with local cerebral injury were the longest or highest. Top 3 drugs in the list of cost were nervous system drugs （178 875 thousand yuan）， blood and hematopoietic agents （61 496 thousand yuan） and anti-infective agents for whole body （49 461 thousand yuan）. Among nervous system drugs， the cost and DDDs of brain protective drugs were the highest. Among patients with different injury severity degrees， average drug cost and hospitalization cost of brain protective drugs group were significantly higher than no treatment group （P＜0.05）， but there was no statistical significance in average hospitalization day between 2 groups （P＞0.05）. Among blood and hematopoietic organ drugs， the cost of blood substitutes and perfusate accounted for the highest proportion， among which intravenous injection， intravenous injection additives， blood and related preparation accounted for 35.5％， 19.17％， 17.17％， respectively. Among anti-infective agents for whole body， top 3 drugs in the list of cost were third-generation cephalosporins， carbapenem and second-generation cephalosporins. Top 3 drugs in the list of DDDs were third-generation cephalosporins， second-generation cephalosporins and fluoroquinolone. CONCLUSIONS： The drugs for traumatic intracranial injury patients are mainly nervous system drug， blood and hematopoietic agents， anti-infective agents for whole body. Most of drugs are symptomatic treatment drugs， and their use is basically reasonable. There still are problems such as brain protective drugs are used too frequently. So， the use of brain protective drugs should be further strengthened and strictly controlled so as to further improve the level of clinical rational drug use.